Literature DB >> 25277501

Biorepository regulatory frameworks: building parallel resources that both promote scientific investigation and protect human subjects.

György Marko-Varga1, Mark S Baker, Emily S Boja, Henry Rodriguez, Thomas E Fehniger.   

Abstract

Clinical samples contained in biorepositories represent an important resource for investigating the many factors that drive human biology. The biological and chemical markers contained in clinical samples provide important measures of health and disease that when combined with such medical evaluation data can aid in decision making by physicians. Nearly all disciplines in medicine and every "omic" depend upon the readouts obtained from such samples, whether the measured analyte is a gene, a protein, a lipid, or a metabolite. There are many steps in sample processing, storage, and management that need to understood by the researchers who utilize biorepositories in their own work. These include not only the preservation of the desired analytes in the sample but also good understanding of the moral and legal framework required for subject protection irrespective of where the samples have been collected. Today there is a great deal of effort in the community to align and standardize both the methodology of sample collection and storage performed in different locations and the necessary frameworks of subject protection including informed consent and institutional review of the studies being performed. There is a growing trend in developing biorepositories around the focus of large population-based studies that address both active and silent nonsymptomatic disease. Logistically these studies generate large numbers of clinical samples and practically place increasing demand upon health care systems to provide uniform sample handling, processing, storage, and documentation of both the sample and the subject as well to ensure that safeguards exist to protect the rights of the study subjects for deciding upon the fates of their samples. Currently the authority to regulate the entire scope of biorepository usage exists as national practice in law in only a few countries. Such legal protection is a necessary component within the framework of biorepositories, both now and in the future. In this brief overview, we provide practical information to the potential users of biorepositories about some of the current developments in both the methodology of sample acquisition and in the regulatory environment governing their use.

Entities:  

Keywords:  LIMS; biobank; ethics; regulatory

Mesh:

Year:  2014        PMID: 25277501     DOI: 10.1021/pr500475q

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  4 in total

1.  Semi-automated biobank sample processing with a 384 high density sample tube robot used in cancer and cardiovascular studies.

Authors:  Johan Malm; Henrik Lindberg; David Erlinge; Roger Appelqvist; Maria Yakovleva; Charlotte Welinder; Erik Steinfelder; Thomas E Fehniger; György Marko-Varga
Journal:  Clin Transl Med       Date:  2015-08-14

Review 2.  Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development.

Authors:  Christine C Roberts
Journal:  Hum Vaccin Immunother       Date:  2019-07-16       Impact factor: 3.452

3.  Merging clinical chemistry biomarker data with a COPD database - building a clinical infrastructure for proteomic studies.

Authors:  Jonatan Eriksson; Simone Andersson; Roger Appelqvist; Elisabet Wieslander; Mikael Truedsson; May Bugge; Johan Malm; Magnus Dahlbäck; Bo Andersson; Thomas E Fehniger; György Marko-Varga
Journal:  Proteome Sci       Date:  2017-04-21       Impact factor: 2.480

4.  Assessment by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry of the Effects of Preanalytical Variables on Serum Peptidome Profiles Following Long-Term Sample Storage.

Authors:  Sachio Tsuchida; Mamoru Satoh; Hiroshi Umemura; Kazuyuki Sogawa; Masaki Takiwaki; Takayuki Ishige; Yui Miyabayashi; Yuuya Iwasawa; Sohei Kobayashi; Minako Beppu; Motoi Nishimura; Yoshio Kodera; Kazuyuki Matsushita; Fumio Nomura
Journal:  Proteomics Clin Appl       Date:  2018-03-02       Impact factor: 3.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.